Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jean-Yves Douillard MD, PhD

Jean-Yves Douillard MD, PhD

Professor Emeritus, Medical Oncology, University of Nantes; Senior Advisor, Integrated Centers of Oncology (ICO), Nantes, France

Dr. Jean-Yves Douillard is a leading international expert in lung cancer and gastrointestinal oncology, and, over the course of a long career, he has held a number of leadership positions, including at the University of Nantes, where he was Professor in Medical Oncology, and at the Integrated Centers of Oncology (ICO) in Nantes, as Head of the Medical Oncology Department and later as Director of Clinical and Translational Research. He has also held senior ESMO positions, serving as Educational Committee Chair and as a member of the Executive Board.

Throughout his career, Dr. Douillard has led clinical trials in lung cancer and gastrointestinal tumors and has investigated targeted therapies, publishing his work in leading scientific journals. His clinical interests also include early drug development and translational research.

Currently, Dr. Doullard is serving as Senior Advisor in early clinical trial research at the Integrated Centers of Oncology.

Recent Contributions to PracticeUpdate:

  1. Activity of FOLFIRI Plus Cetuximab According to Extended Gene Mutation Status
  2. Dr. Jean-Yves Douillard’s ASCO 2014 LBA Pick for Lung Cancer
  3. Dr. Jean-Yves Douillard’s 2014 ASCO Abstract Recommendations—Lung Cancer
  4. Progress in NSCLC Molecular Characterization for Personalized Medicine
  5. Genotyping cfDNA for Tumor Alterations
  6. Noninvasive Detection of Response/Resistance in EGFR-Mutant Lung Cancer Using Cell-Free Plasma DNA
  7. 2013 Top Stories in Oncology: Lung Cancer
  8. Frequently Asked Questions in Oncology: Lung Cancer
  9. PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
  10. Take-Home Messages in Lung Cancer From the 2013 European Cancer Congress

Most Read This Week

Recently Updated